Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,643 INR | +0.13% | +6.08% | +10.29% |
Feb. 02 | Transcript : Poly Medicure Limited, Q3 2024 Earnings Call, Feb 02, 2024 | |
Jan. 31 | Poly Medicure Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 61.69 times its estimated earnings per share for the ongoing year.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+10.29% | 1.89B | - | ||
-3.43% | 184B | C+ | ||
-1.81% | 107B | C | ||
-4.15% | 67.78B | A | ||
+1.43% | 50.66B | B- | ||
+11.60% | 47.64B | B- | ||
+4.60% | 41.12B | B+ | ||
+3.03% | 26.3B | B | ||
+3.21% | 26.04B | A- | ||
+15.06% | 25.4B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- POLYMED Stock
- POLYMED Stock
- Ratings Poly Medicure Limited